Determination of association between the polymorphism in exon 3 of dopamine receptor gene type 4 with attention deficit-hyperactivity disorder

Introduction: Evidences suggest that attention deficit-hyperactivity disorder (ADHD) is a hereditary disorder and at least 20 potential genes associated with ADHD have been identified. Dopamine receptor gene type 4 (DRD4) has been more considered due to a stronger relationship with ADHD. However, no study has yet been conducted on the Iranian population to assess the association. Objective: In this study, the association between polymorphism of DRD4 gene with ADHD has been studied among capital of Iran population. Materials and methods: This study is a case-control study conducted on children aged 6�12 years with ADHD referred to child and adolescent psychiatric clinic Imam Hussein (AS) and normal subjects in 2011. Diagnosis was done based on the DSM-IV-TR criteria and interviewing by two child and adolescent psychiatrists. If parental were consent, then saliva samples of subjects were prepared and DRD4 gene and related allele were evaluated using PCR method. The K-SADS questionnaire was also used to assess comorbid disorders. Results: In this study, 114 patients in ADHD group and 109 patients in the control group were studied. The most frequency was obtained for allele 4 allele that has been observed in about 90 of both case and control groups. However, frequency of allele 6 in the case group was 8.8 where the frequency was 5 in the control group (p = 0.02). The presence of repeat of allele 6 increased chance of suffering from ADHD to 1.809 (95 equal to 3.871�0.845). Conclusion: For the first time this study showed that in Iranian population repeat of DRD4 gene allele 6 unlike the other geographic areas is relatively common and it will increase the chances of suffering from ADHD. However, additional studies are required. © 201

Heat treatment of cold-sprayed C355 Al for repair: microstructure and mechanical properties

Cold gas dynamic spraying of commercially pure aluminum is widely used for dimensional repair in the aerospace sector as it is capable of producing oxide-free deposits of hundreds of micrometer thickness with strong bonding to the substrate, based on adhesive pull-off tests, and often with enhanced hardness compared to the powder prior to spraying. There is significant interest in extending this application to structural, load-bearing repairs. Particularly, in the case of high-strength aluminum alloys, cold spray deposits can exhibit high levels of porosity and microcracks, leading to mechanical properties that are inadequate for most load-bearing applications. Here, heat treatment was investigated as a potential means of improving the properties of cold-sprayed coatings from Al alloy C355. Coatings produced with process conditions of 500 °C and 60 bar were heat-treated at 175, 200, 225, 250 °C for 4 h in air, and the evolution of the microstructure and microhardness was analyzed. Heat treatment at 225 and 250 °C revealed a decreased porosity (~ 0.14% and 0.02%, respectively) with the former yielding slightly reduced hardness (105 versus 130 HV0.05 as-sprayed). Compressive residual stress levels were approximately halved at all depths into the coating after heat treatment, and tensile testing showed an improvement in ductility

Advances in understanding and treating ADHD

Attention deficit hyperactivity disorder (ADHD) is a neurocognitive behavioral developmental disorder most commonly seen in childhood and adolescence, which often extends to the adult years. Relative to a decade ago, there has been extensive research into understanding the factors underlying ADHD, leading to far more treatment options available for both adolescents and adults with this disorder. Novel stimulant formulations have made it possible to tailor treatment to the duration of efficacy required by patients, and to help mitigate the potential for abuse, misuse and diversion. Several new non-stimulant options have also emerged in the past few years. Among these, cognitive behavioral interventions have proven popular in the treatment of adult ADHD, especially within the adult population who cannot or will not use medications, along with the many medication-treated patients who continue to show residual disability

Six week open-label reboxetine treatment in children and adolescents with attention deficit hyperactivity disorder

Background: Attention Deficit Hyperactivity Disorder (ADHD) is a common psychiatric disorder among children and adolescents. This disorder causes difficulties in academic, behavioral, emotional, social and family performance. Stimulants show robust efficacy and a good safety profile in children with this disorder, but a significant percent of ADHD children do not respond adequately or cannot tolerate the associated adverse effects with stimulants. Such difficulties highlight the need for alternative safe and effective medications in the treatment of this disorder. This open-label study assessed the effectiveness of reboxetine, a selective norepinephrine reuptake inhibitor, in children and adolescents with attention deficit hyperactivity disorder (ADHD)."nMethods: Fifteen child and adolescent outpatients, aged 7 to 16 (Mean± SD=9.72±2.71) years, diagnosed with ADHD were enrolled in a six open-label study with reboxetine 4-6 mg/d. The principal measure of the outcome was the teacher and parent Attention Deficit Hyperactive Disorder Rating Scale (ADHD Rating Scale). Patients were assessed by a child psychiatrist at baseline, 2, 4 and 6 weeks of the medication started. Side effects questionnaire was used to detect side effects of reboxetine. Repeated measures Analysis of variance (ANOVA) was done for comparison of Teacher and Parent ADHD Rating Scale scores during the intervention."nResults: Twelve of 15 (80%) participants completed the treatment protocol. A significant decrease in ADHD symptoms on teacher (p=0.04) and parent (p=0.003) ADHD rating scale was noted. Adverse effects were mild to moderate in severity. The most common adverse effects were drowsiness/sedation and appetite decrease."nConclusion: The results of the current study suggest the effectiveness of reboxetine in the treatment of ADHD in children and adolescents. Double-blind, placebo-controlled studies and larger sample size with long duration of intervention are indicated to rigorously test the efficacy of reboxetine in ADHD. It is important that future studies complete our knowledge about safety and side effects of reboxetine